Perspective Therapeutics

CATX

Market cap $175M

SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

Perspective Therapeutics, Inc. ( CATX ) UBS Global Healthcare Conference 2025 November 11, 2025 4:15 PM EST Company Participants Joel Sendek - Chief Financial Officer Annie Cheng - Vice President of Investor Relations Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division Great. Thanks, everyone, for joining us.

SEATTLE, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended September 30, 2025.

SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Perspective Therapeutics, Inc. (NYSE:CATX ) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO October 20, 2025 8:30 AM EDT Company Participants Annie Cheng - Vice President of Investor Relations Johan Spoor - CEO & Director Markus Puhlmann - Chief Medical Officer Steve Keefe - Senior Vice President of Clinical Development Conference Call Participants Richard Wahl Leonid Timashev - RBC Capital Markets, Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Alec Stranahan - BofA Securities, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Phillip Eckert - LifeSci Capital, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division David Nierengarten - Wedbush Securities Inc., Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Presentation Operator Greetings.

SEATTLE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial (NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) were presented at the European Society for Medical Oncology (ESMO) Congress 2025 taking place October 17-21, 2025 in Berlin, Germany.

SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today.

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences.

SEATTLE, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2025.